Literature DB >> 6248817

Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.

M B Lees, V S Sapirstein, D S Reiss, E H Kolodny.   

Abstract

The activities of carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase (CNPase) were measured in gray and white matter and in myelin from human brains obtained at autopsy. Carbonic anhydrase activity increased with age, and at all ages a major part of the activity was associated with membrane fractions. The percentage of membrane-bound carbonic anhydrase was lower than normal in white matter from Krabbe disease and adrenoleukodystrophy; isolated myelin had a low specific activity in these diseases. CNPase activity was decreased in both white matter and myelin, but was somewhat higher than normal in gray matter. Although the yield of myelin from a case of metachromatic leukodystrophy was markedly reduced, changes in the enzymes activities were minimal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248817     DOI: 10.1212/wnl.30.7.719

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  A comparison of the glycoproteins and the proteins from multiple sclerosis and normal brain tissue.

Authors:  M T Filbin; S E Poduslo
Journal:  Neurochem Res       Date:  1986-08       Impact factor: 3.996

2.  Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.

Authors:  W S Sly; D Hewett-Emmett; M P Whyte; Y S Yu; R E Tashian
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

3.  Progressive damage along the optic nerve following induction of crush injury or rodent anterior ischemic optic neuropathy in transgenic mice.

Authors:  O Dratviman-Storobinsky; M Hasanreisoglu; D Offen; Y Barhum; D Weinberger; N Goldenberg-Cohen
Journal:  Mol Vis       Date:  2008-11-30       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.